Combined topical therapy mixture can effectively and rapidly control atopic dermatitis lesions- a pilot study
Keywords:
Atopic dermatitis, combined therapy, emollient, topical antibiotics, topical steroidsAbstract
Background Topical steroids are the mainstay of therapy in atopic dermatitis. However, as massive colonization of lesional and non-lesional skin of atopic dermatitis patients with Staphylococcus aureus has been proved to exist and aggravate the skin lesions, thus topical antibiotics seem necessary to be added. New combined topical antibiotics and steroid formula eliminate forcefully the organism. Moreover, as topical medication penetrates a moist stratum corneum more effectively than it will penetrate a dehydrated stratum corneum, thus combining an emollient to atopic dermatitis therapy seems of utmost importance. Objective To evaluate the effectiveness of combining two topical steroids, an antibiotic and an emollient as a single mixture in effectively controlling atopic dermatitis lesions in a six weeks treatment period. Subjects and methods Thirty one females with atopic dermatitis were enrolled in this study. Disease severity was measured using the Severity Score of Atopic Dermatitis (SCORAD) index at baseline, 3 weeks and 6 weeks of therapy. They were treated with a mixture of mometasone furoate, fusidic acid and betamethasone valerate twice daily for six weeks. Results Out of the 31 enrolled cases, 20 (64.5%) satisfied the inclusion criteria. They all completed the 6-week treatment regimen and evidenced no side effects from therapy. Statistical comparison between baseline and after three and six weeks interval using ANOVA and Tukey's multiple comparison tests revealed significant improvement of SCORAD index and its six clinical intensity signs with more effective improvement after the 6-week therapy. No correlation was ever detected by the Spearman test between index score and lesions' site or with allergic co-morbidities. Conclusion The combined topical therapy mixture was effective and safe in rapidly controlling treated lesions.ÂReferences
Atherton DJ. Topical corticosteroids in atopic dermatitis. Recent research reassures that they are safe and effective in the medium term. BMJ 2003; 327: 942-3.
Green C, Colquitt JL, Kirby J et al. Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iii,iv, 1-120.
Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1974; 90: 525-30.
Hoeger PH, Lenz W, Boutonnier A, Fournier JM. Staphylococcal skin colonization in children with atopic dermatitis; prevalence, persistence and transmission of toxigenic and nontoxigenic strains. J Infect Dis 1992; 165: 1064-8.
Goodyear HM, Watson PJ, Egan SA et al. Skin microflora in of atopic dermatitis in first time hospital attenders. Clin Exp Dermatol 1993; 18: 300-4.
Dhar S, Kanwar AJ, Kaur S et al. Role of bacterial flora in the pathogenesis and management of atopic dermatitis. Ind J Med Res 1992; 95: 234-8.
White MI, and Noble WC. Consequences of colonization and infection by Staphylococcus aureus in atopic. Exp Dermatol 1986; 11: 34-40.
Hauser C, Wuetrich B, Matter L et al. Staphylococcus aureus skin colonization in atopic dermatitis. Dermatologica 1985; 170: 35-9.
McFadden JP, Noble WC, Camp RD. Superantigenic exotoxin secreting potential of staphylococci isolated from eczematous skin. Br J Dermatol 1993; 128: 631-2.
Dhar S. Should topical antibacterials be routinely combined with topical steroids in the treatment of atopic dermatitis? Ind J Dermatol Venereol Leprol 2005; 71: 71-2.
Proksch E. The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol 2008; 21: 75-80.
Eichenfield LF, Hanifin JM, Luger TA et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003; 49: 1088-95.
Gambichler T. Narrowband UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol 2005; 52: 660-70.
Ellis C, Luger T, Abeck D et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003; 148 (suppl 63): 3-10.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatol Venereol (Stockh) 1980: 92: 44-7.
Stalder JF, Tateb A. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993: 186: 23-31.
Williams H. New treatments for atopic dermatitis. BMJ 2002; 324: 1533-4.
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic eczema. Health Technol Assess 2000; 4: 191-1.
Du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol 1976; 112: 1245-8.
Lagos BR, Maibach HI. Frequency of application of topical corticosteroids: an overview. Br J Dermatol 1998; 139: 763-6.
Kerscher MJ, Hart H, Korting HC, Stalleicken D. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocoticoids old and new. Int J Clin Pharmacol Ther 1995; 33: 187-9.
Rajka G, Avrach W, Gartner L, Overgaard-Petersen H. Mometasone furoate 0.1% fatty cream once daily versus betamethasone valerate 0.1% cream twice daily in the treatment of patients with atopic and allergic contact dermatitis. Cur Ther Res Clin Exp 1993; 54: 23-9.
Hoybye S, Balk MS, De Cunha BF et al. Continuous and intermittent treatment of atopic dermatitis in adults with mometasone furoate versus hydrocortisone 17-butyrate. Cur Ther Res Clin Exp 1991; 50: 67-72.
British Association of Dermatology. Guidelines for the management of atopic eczema. URL: www.bad.org.uk/doctors/service%-provision/primary/ eczema.htm. Accessed August 2003.
Breuer K, Haussler S, Kapp A et al. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br J Dermatol 2002; 147: 55-61.
Goh CL, Wong JS, Giam YC. Skin colonization of Staphylococcus aureus in atopic dermatitis patients seen at the National Skin Center, Singapore. Int J Dermatol 1997; 36: 653-7.
William REA, Gibson AG, Aitchison TC et al. Assessment of a contact- plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. Br J Dermatol 1990; 123: 493-501.
Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. Int J Dermatol 1999; 38: 265-9.
Boguniewicz M, Sampson H, Leung SB et al. Effects of cefuroxime axetil on S. aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001; 108: 651-2.
Ewing CI, Ashcroft C, Gibbs AC et al. Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol 1998; 138: 1022-9.
Stadler JF, Fleury M, Sourisse M et al. Local steroid therapy and bacterial skin flora in atopic dermatitis. Br J Dermatol 1994; 131: 536-40.
Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and Staphylococcus aureus in atopic dermatitis. J Am Acad Dermatol 1992; 27: 29-34.
Wachs GN, Maibach HI. Co-operative double-blind trial on an antibiotic/corticoid combination in impeginized atopic dermatitis. Br J Dermatol 1976; 95: 323-8.
Abeck D, Mempel M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998; 139 (Suppl. 53): 13-6.
Khobragade KJ. Efficacy and safety of combination ointment fluticasone propionate 0.005% plus mupirocin 2% for the treatment of atopic dermatitis with clinical suspicion of secondary bacterial infection: An open label uncontrolled study. Ind J Dermatol Venereol Leprol 2005; 71: 92-6.
Gong J.Q, Lin L, Lin T et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006; 155: 680-7.
Ravenscroft JC, Layton AM, Eady EA et al. Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema. Br J Dermatol 2003; 148: 1010-7.
Hjorth N, Schmidt H, Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126-31.
Larsen FS, Simonsen L, Melgaard A et al. An efficient new formulation of fusidic acid and betamethasone 17-valerate (fucicort lipid cream) for treatment of clinically infected atopic dermatitis. Acta Derm Venereol 2007; 87: 62-8.
Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441-6.
Grimalt R, Mengeaud V, Cambazard F. Study Investigators Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007; 214: 61-7.
Hanifin JM, Hebert AA, Mays SR et al. Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res 1998; 59: 227-33.
Kampf G, Wigger-Alberti W, Schoder V, Wilhelm KP. Emollients in a propanol-based hand rub can significantly decrease irritant contact dermatitis. Contact Dermatitis 2005; 53: 344-9.
Szczepanowska J, Reich A, Szepietowski JC. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study. Pediatr Allergy Immunol 2008; 19: 614-8.
